ASTONISH confirms the therapeutic potential of nangibotide in septic shock patients with excessive activation of the TREM-1 pathwayASTONISH confirms that the soluble TREM-1 biomarker predicts response to nangibotide treatmentPARIS (BUSINESS WIRE) #biotech Inotrem, an advanced clinical stage biotech company specia.